钟志远

姓  名：钟志远

职称职务：特聘教授、bat365中文官方网站院长

电子邮箱：zyzhong@suda.edu.cn

办公地址：云轩楼E01-1336

一、个人简介

苏州大学特聘教授、bat365中文官方网站院长、生物医用高分子材料重点实验室主任、江苏省先进功能高分子材料设计及应用重点实验室主任、放射医学与辐射防护国家重点实验室放药中心主任。美国医学与生物工程院会士(AIMBE Fellow)，药剂学TOP期刊Journal of Controlled Release（IF 11.467)副主编。自2014年起连续9年入选中国高被引学者榜单,自2018年起连续4年入选全球高被引科学家。曾任Biomacromolecules副主编（2015-1019）和苏州工业园区生物产业发展有限公司（苏州生物医药产业园）副总裁（2011-2012）。

现主持1项国家基金委重点项目和2项国家重点研发计划项目课题。研究领域涉及药物控制释放（包括化药、蛋白和核酸药物、核药等）、肿瘤靶向治疗和免疫治疗。在国际主流期刊发表论文300多篇，论文共被引用23000多次，H-因子79。授权50多项国家和国际发明专利（转让12项）。担任Mater. Today, Acta Pharmaceutica Sinica B, Biomacromolecules, Nanotechnology, PLoS One, Mater. Today Chem., J. Gene Med., J. Biomater. Sci. Polym. Ed.等8本国际期刊及《药学学报》编委。担任新型高分子材料与控制释放系列高水平国际学术会议主席。应邀在重要国际学术会议上做邀请报告50多次。

入选国家杰出青年科学基金获得者（杰青结题特优）、国家“万人计划”创新领军人才、国家百千万人才工程并授予“有突出贡献中青年专家”荣誉称号、科技部中青年科技创新领军人、江苏特聘教授、苏州市十佳魅力科技人物、苏州市先进教育工作者等。荣获美国化学会的“生物大分子/大分子青年研究者奖”、德国洪堡基金会“贝塞尔研究奖” 、日本控制释放学会颁发的“亚洲药物释放系统突破技术奖”等国际奖励。享受国务院政府特殊津贴。

二、学习和工作经历

1991.9-1995.7，吉林大学（原吉林工业大学）应用化学系,本科

1995.9-1998.7，中国科学院长春应用化学研究所，硕士

1998.10-2002.10，荷兰屯特大学 (University of Twente)，博士

2002.10-2007.4，荷兰屯特大学 (University of Twente)生物医学技术研究所，助理教授

2004.9-2004.10，美国犹他大学(University of Utah) bat365中文官方网站，访问学者

2007.4-至今，苏州大学特聘教授，生物医用高分子材料重点实验室主任

2011.9-2012.8月，苏州生物医药产业园（BioBAY）副总裁

2019.7-至今，放射医学与辐射防护国家重点实验室靶向放药中心主任

2021.9-至今，江苏省先进功能高分子材料设计及应用重点实验室主任

2021.12-至今，bat365中文官方网站院长

三、研究方向

药物控制释放（包括化药、蛋白药、核酸药物、核素等）、智能纳米药物、肿瘤靶向治疗、免疫治疗

四、招生招聘

招收有志从事前沿生物医药研发工作的优秀博士研究生、博士后、专职科研人员（研究员或副研究员）、海外优青。
联系方式：zyzhong@suda.edu.cn

通讯地址：bat365中文官方网站云轩楼1336室 

五、近5年代表性论文

（1）J. Sun, Z.Y. Huangfu, J.T. Yang, G.L. Wang*, K. Hu*, M.Y. Gao, Z.Y. Zhong*, Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation, Adv. Drug Deliv. Rev. 2022, 190, 114538.

（2）X.Y.Ji*, Z.Y. Zhong*, External stimuli-responsive gasotransmitter prodrugs: Chemistry and spatiotemporal release, J. Control. Release 2022, 351, 81-101.

（3）J.J. Jiang, R.X. Wang, L. Yang, Y.J. Sha, S.S. Zhao, D.F. Chen*, Z.Y. Zhong*, F.H. Meng*, IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma, J. Control. Release 2022, 350, 460-470.

（4）J.Y. Liu, L. Zhang, D.X. Zhao, S.J. Yue, H.L. Sun*, C.F. Ni*, Z.Y. Zhong*, Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy, J. Control. Release 2022, 350, 122-131.

（5）H. Zheng, B.B. Guo, X.Y. Qiu, Y.F. Xia, Y. Qu, L. Cheng*, F.H. Meng*, Z.Y. Zhong*, Polymersome-Mediated Cytosolic Delivery of Cyclic Dinucleotide STING Agonist Enhances Tumor Immunotherapy, Bioactive Mater.2022, 16, 1-11.

（6）Y. Zheng*, Z.Y. Zhong*, Roadmap to next-generation cancer vaccines, J. Control. Release 2022, 347, 308-313.

（7）J.J. Wei, D. Wu, Y. Shao, B.B. Guo, J.J. Jiang, J. Chen, J.P. Zhang, F.H. Meng*, Z.Y. Zhong*, ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy, J. Control. Release 2022, 347, 68-77.

（8）J.J. Wei, D. Wu, S.S. Zhao, Y. Shao, Y.F. Xia, F.H. Meng*, D.W. Ni, X.Y. Qiu, J.P. Zhang, J. Chen*, and Z.Y. Zhong*, Immunotherapy of Malignant Glioma by Non-Invasive Administration of TLR9 Agonist CpG Nano-immunoadjuvant, Adv. Sci.2022, 9, 2103689.

（9）H.H. Fang, Y.J. Sha, L. Yang, J.J. Jiang, L.C. Yin, J.Y. Li, B. Li, B. Klumperman, Z.Y. Zhong*, and F.H. Meng*,  Macrophage-Targeted Hydroxychloroquine Nanotherapeutics for Rheumatoid Arthritis Therapy, ACS Appl. Mater. Interfaces 2022, 14, 8824-8837.

（10）Z. Wang, S.S. Zhao, F.H. Meng*, J.D. Yuan, andZ.Y. Zhong*, Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics, Acta Biomaterialia 2022, 138, 443-452.

（11）X.Y.Qiu, Y.Qu, B.B.Guo, H.Zheng, F.H. Meng*, andZ.Y. Zhong*, Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer, J. Control. Release 2022, 341, 498-510.

（12）Y.F. Zhang, S.J. Yue, H.L. Sun*, R. Haag, Z.Y. Zhong*, An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer, J. Control. Release2021, 340, 331-341.

（13）Z. Wang, F.H. Meng, and Z.Y. Zhong*, Emerging targeted drug delivery strategies toward ovarian cancer, Adv. Drug Deliv. Rev. 2021, 178, 113969

（14）N. Yu, Y.F. Zhang, J.Y. Li, W.X. Gu, S.J. Yue, B. Li, F.H. Meng, H.L. Sun*, R. Haag, J.D. Yuan, andZ.Y. Zhong*, Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma, Adv. Mater.2021, 33, 2007787.

（15）Y.H. Wei, Y.P. Sun, J.J. Wei, X.Y. Qiu, F.H. Meng*, G. Storm*, J.D. Yuan, Z.Y. Zhong*, Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo, J. Control. Release2021, 337, 521-529.

（16）W.X. Gu, R.B. Qu, F.H. Meng*,J.L.M. Cornelissen*, andZ.Y. Zhong*,Polymeric Nanomedicines Targeting Hematological Malignancies, J. Control. Release 2021, 337, 571-588.

（17）Y.F. Xia, J.J. Wei, S.S. Zhao, B.B. Guo, F.H. Meng*, B. Klumperman, andZ.Y. Zhong*,Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma, J. Control. Release 2021, 336, 262-273.

（18）Q.Y. Fan, Y.Y. Liu, G.H. Cui, Z.Y. Zhong*,andC. Deng*, Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma, J. Control. Release 2021, 329, 1139-1149.

（19）W.X. Gu, T.H. Liu, D.Y. Fan, J.B. Zhang, Y.F. Xia, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, Z.J. Liu, andZ.Y. Zhong*, A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia, J. Control. Release 2021, 329, 706-716.

（20）W.X. Gu, F.H. Meng*, R. Haag, andZ.Y. Zhong*, Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation, J. Control. Release 2021, 329, 676-695.

（21）C. Gao, Q. Cheng, J.W. Wei, C. Sun, S.Y. Lu, C.H.T. Kwong, S.M.Y. Lee, Z.Y. Zhong*, and R.B. Wang*, Bioorthogonal supramolecular cell-conjugation for targeted hitchhiking drug delivery, Mater. Today2020, 40, 9-17.

（22）C. Deng*, Q. Zhang, J.Q. Guo, X.F. Zhao, and Z.Y. Zhong*, Robust and smart polypeptide-based nanomedicines for targeted tumor therapy, Adv. Drug Deliv. Rev. 2020, 160, 199-211.

（23）H.L. Sun, and Z.Y. Zhong*, 100^th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery, ACS Macro Lett. 2020, 9, 1292-1302.

（24）Y.W. Li, J.J. Wei, Y.H. Wei, L. Cheng*, B.B. Guo, F.H. Meng*, F. Li, andZ.Y. Zhong*, Apolipoprotein E Peptide-Guided Disulfide-Crosslinked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma, Biomacromolecules2020, 21, 716-724

（25）Y.H. Wei, F.H. Meng*, G. Storm, and Z.Y. Zhong*, Transferrin-Binding Peptide Functionalized Polymersomes Mediate Targeted Doxorubicin Delivery to Colorectal Cancer In Vivo, J. Control. Release 2020, 319, 407-415.

（26）Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J. van Hest, andZ.Y. Zhong*, CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma in Mice, J. Control. Release2020, 320, 421-430.

（27）X.L. Gu, Z.H. Zhu, Y.H. Wei, G.L. Wang, F.H. Meng, Z.Y. Zhong*, and C. Deng*, Nano-Agents Based on Poly(ethylene glycol)-b-Poly(L-thyroxine) Block Copolypeptide for Enhanced Dual-Modality Imaging and Targeted Tumor Radiotherapy, Small 2019, 15, 1902577.

（28）Y. Zou, Y.H. Wei, J. Bao, F.R. Yao, Z.K. Li, Y.P. Sun, F.H. Meng*, C.H. Hu, G. Storm, andZ.Y. Zhong*, Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Melanoma, Theranostics2019, 9, 8061-8072.

（29）H.L. Sun, Z.Y. Zhong*, and J. Feijen, The Fifth Symposium on Innovative Polymers for Controlled Delivery, September 14-17, 2018, Suzhou, China, J. Control. Release2019, 307, 410-412.

（30）W.X. Gu, J.N. An, H. Meng, N. Yu, Y.N. Zhong, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, andZ.Y. Zhong*, CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma, Adv. Mater.2019, 1904742.

（31）H.Z. Qin, Y. Jiang, J. Zhang, C. Deng*, and Z.Y. Zhong*, Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals a High Safety and Potency against Human Glioblastoma in Mice, Mol. Pharmaceutics 2019, 16, 3711-3719.

（32）M. Qiu, J. Ouyang, Y.H. Wei, J. Zhang, Q. Lan, C. Deng*, and Z.Y. Zhong*, Selective cell penetrating peptide-functionalized envelope-type chimaeric lipopepsomes boost systemic RNAi therapy for lung tumor, Adv. Healthcare Mater. 2019, 1900500.

（33）X.L. Gu, Y.H. Wei, Q.Y. Fan, H.L. Sun, R. Cheng, Z.Y. Zhong*, and C. Deng*, cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo, J. Control. Release 2019, 301, 110-118.

（34）N. Rades, K. Achazi, M. Qiu, C. Deng, R. Haag, Z.Y. Zhong*, and K. Licha*, Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs, J. Control. Release 2019, 300, 13-21.

（35）Y. Zou, J.J. Wei, Y.F. Xia, F.H. Meng*, J.D. Yuan, andZ.Y. Zhong*,Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin, Signal Transduction and Targeted Therapy2018, 3, 32.

（36）Y. Jiang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*,Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma,ACS Nano2018, 12, 11070-11079.

（37）L. Cheng, Y. Yang, F.H. Meng*, Z.Y. Zhong*, Protein Nanotherapeutics as an Emerging Modality for Cancer Therapy, Adv. Healthcare Mater.2018, 7, 1800685.

（38）M. Qiu, X.X. Wang, H.L. Sun, J. Zhang, C. Deng*, and Z.Y. Zhong*, Cyclic RGD Peptide-Functionalized Polylipopeptide Micelles for Enhanced Loading and Targeted Delivery of Monomethyl Auristatin E, Mol. Pharmaceutics 2018, 15, 4854-4861.

（39）Y.N. Shi, Y. Jiang, J.S. Cao, W.J. Yang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*,Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes,J. Control. Release2018, 292, 163-171.

（40）H.L. Sun, Y.F. Zhang, and Z.Y. Zhong*, Reduction-Sensitive Polymeric Nanomedicines: An Emerging Multifunctional Platform for Targeted Cancer Therapy, Adv. Drug Deliv. Rev.2018, 132, 16-32.

（41）M. Qiu, Z.Q. Zhang, Y.H. Wei, H.L. Sun, F.H. Meng, C. Deng*, and Z.Y. Zhong*, Small-Sized and Robust Chimaeric Lipopepsomes: A Simple and Functional Platform with High Protein Loading for Targeted Intracellular Delivery of Protein Toxin In Vivo, Chem. Mater. 2018, 30, 6831-6838.

（42）W.J. Yang, Y.H. Wei, J. Zhang, Z.Y. Zhong*, F.H. Meng*,Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo, J. Control. Release2018, 290, 141-149.

（43）H.L. Sun, Y.Y. Dong, J. Feijen*, and Z.Y. Zhong*, Peptide-Directed Polymeric Nanomedicines for Precision Cancer Therapy, J. Control. Release2018, 290, 11-27.

（44）Y. Jiang, W.J. Yang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*,Protein Toxin Chaperoned by LRP-1 Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo,Adv. Mater.2018, 30, 1800316.

（45）W.J. Yang, Y.F. Xia, Y. Fang, F.H. Meng*, J. Zhang, R. Cheng, C. Deng, and Z.Y. Zhong*, Selective Cell Penetrating Peptide-Functionalized Polymersomes Mediate Efficient and Targeted Delivery of Methotrexate Disodium to Human Lung Cancer In Vivo, Adv. Healthcare Mater.2018, 7, 1701135.

（46）Y.Q. Zhu, Y. Jiang, F.H. Meng, C. Deng, R. Cheng, J. Zhang*, J. Feijen*, and Z.Y. Zhong*, Highly efficacious and specific anti-glioma chemotherapy by smart tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides,J. Control. Release2018,278, 1-8.

（47）Y.Q. Zhu, J. Feijen*, and Z.Y. Zhong*, Dual-Targeted Nanomedicines for Enhanced Tumor Treatment,Nano Today2018, 18, 65-85.

（48）M. Qiu, H.L. Sun, F.H. Meng, R. Cheng, J. Zhang, C. Deng*, and Z.Y. Zhong*, Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo, J. Control. Release2018, 272, 107-113.